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ABSTRACT

In previous experiments, the steroidal saponin, dioscin, which was extracted
from the roots of the wild yam (Dioscorea villosa), was observed to have potent antiproliferative effects on the human breast cancer cell lines MCF-7 and MDA-MB-231.
Dioscin was also able to activate the transcription of tumor suppressor genes
GATA3 and CDH1 in these cell lines. We hypothesize that the anti-proliferative effect
of dioscin on human breast cancer cells could be mediated through the epigenome.
Consequently, in order to explore this hypothesis, we have analyzed the expression
of DNA methyltransferase 1 (DNMT1) protein in these cells. MCF-7 and MDA-MB231 cells were treated with differing concentrations of dioscin, as well as a 1μM
concentration of the known DNMT1 inhibitor, 5-azacytidine. Protein lysate was
collected from these cells and was then subjected to Western blot analysis. Both
dioscin and 5-azacytidine decreased protein expression of the DNMT isoform with a
molecular weight of 145 kDa. It may be concluded that dioscin has potential DNMT1
inhibiting ability, but whether or not this ability directly contributes to dioscin’s
anti-proliferative effects and the activation of the tumor suppressor genes GATA3
and CDH1 remains to be seen.
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Introduction

Breast cancer has become one of the most frequently diagnosed cancers in
the United States today. The American Cancer Society estimates that 1 in 8 women
will acquire invasive breast cancer in their lifetime, making it the second most
prevalent cancer in women behind skin cancer. Although the mortality rate has
dropped over the years, breast cancer is responsible for 40,000 deaths per year in
the United States alone (Lu et al. 2009). These deaths are mostly attributed to the
reoccurrence of the cancer, which frequently present with metastases (Lu et al.
2009). Metastatic breast cancer today is generally treated with a cocktail of
cytotoxic drugs that can immensely reduce the patient’s quality of life and allow the
cancer to develop a drug resistance quite quickly. The search for a viable anticancer/anti-metastatic agent is still very much alive due to the devastating side
effects of most known drugs.
For many years, it was thought that the mechanisms behind breast cancer
were genetic alterations. In other words, breast cancer resulted from direct changes
in the DNA code, such as deletions, point mutations, and chromosome
rearrangements (Aumsuwan et al. 2016). However, it is now known that breast
cancer not only arises from genetic alterations, but also from epigenetic
modifications (Aumsuwan et al. 2016). Epigenetics is a rapidly growing field in
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cancer research, mainly because epigenetic modifications are enzyme-regulated
processes; they do not affect the primary DNA sequence and are able to be reversed,
making epigenetic drugs an exciting prospect for cancer therapies. The most
common types of epigenetic alterations are histone modifications, DNA methylation,
and noncoding RNA interface (Aumsuwan et al. 2016). While all of these epigenetic
mechanisms have been found to be altered in cancer cells, we know the most about
DNA methylation and will focus mainly on this process.
DNA methylation is an epigenetic mechanism where a methyl group (CH3) is
added to the DNA, thereby altering the function of a gene. In mammals, DNA
methylation occurs mostly on C-5 of cytosine at CpG sites, which are cytosineguanine (CG) dinucleotide sequences associated with gene promoters (Carey, 2013).
When these CpG sites are not extensively methylated, the chromatin structure is
loosely packed, the gene promoter region is unhindered, and transcription of the
gene proceeds (Neidhart, 2016). In contrast, when CpG sites are highly methylated,
chromatin structure becomes compacted, transcription activators are unable to bind
to the promoter region, and gene transcription is shut off (Neidhart, 2016). DNA
methylation therefore provides an efficient way to regulate gene expression,
because the effects are reversible. Cancers are able to abuse this regulation
pathway, however, by altering the promoter regions of tumor suppressor genes,
proto-oncogenes, and other genes associated with DNA repair pathways (Carey,
2013). When the promoter regions on tumor suppressor genes and DNA repair
genes are highly methylated, the genes are inactivated and tumor growth is unable
to be held in check. In breast cancer alone, over 100 different tumor suppressor
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genes have been shown to be hypermethylated (Hinshelwood et al. 2008). Cancers
are able to accomplish this uncontrolled tumorigenesis by hijacking the enzymes
responsible for DNA methylation.
It is now documented that breast cancer, along with various other cancers, is
able to silence tumor suppressor genes through the abnormal functioning and
expression of DNA methyltransferases (DNMTs)(Aumsuwan et al. 2015). These
enzymes catalyze the addition of methyl groups to the CpG sites, and function in the
maintenance of genomic stability. There are three different DNMTs that possess this
enzymatic activity: DNMT1, DNMT3A, and DNMT3B. DNMT1 is described as the
“maintenance” methyltransferase and is the most prevalent DNMT in somatic cells
(Robertson et al. 2001). The “maintenance” activity refers to the ability of the
methyltransferase to recognize hemimethylated DNA and add the corresponding
methyl group to the complementary strand (Chen et al. 2011). For this reason,
DNMT1 is generally responsible for maintaining DNA methylation patterns after
DNA replication has occurred. DNMT3A and DNMT3B comprise the family of what is
known as the de novo methyltransferases. These DNMTs add methyl groups to
completely unmethylated DNA, and are in charge of setting the patterns of
methylation early on in development and in cell differentiation (Chen et al. 2011).
The roles of the maintenance and de novo DNMTs do show some overlap, however,
as DNMT3A and DNMT3B may be able methylate certain CpG sites that were
skipped over by DNMT1 (Chen et al. 2011). In addition to these three catalytically
conserved enzymes, there are two other DNMTs in the human body that need
mentioning. DNMT3L does not possess any inherent enzymatic activity, but it is able
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to recruit DNMT3A/3B and stimulate their activity (Chen et al. 2011). A separate
methyltransferase, DNMT2, has not been shown to be very active in DNA
methylation, but instead has been shown to methylate tRNAs and protect them from
cleavage (Ghanbarian et al. 2016). Although these two methyltransferases are a part
of the DNMT family, they do not directly catalyze the addition of a methyl group to
CpG sites in humans.

Figure 1: A: The addition of a C-5 methyl group catalyzed by DNMT. B: The
mechanisms of maintenance methylation by DNMT1 vs de novo methylation by
DNMT3A/3B. (Chen et al. 2011)
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Although the exact mechanisms are still unknown, cancers are able to
atypically express these DNMTs and disturb normal DNA methylation patterns (Jin
et al. 2013). A recent study was able to demonstrate that DNMT1 is overexpressed
in mammary tumors and is essential for both mammary stem cell and cancer stem
cell maintenance (Pathania et al. 2015). In the experiment, they introduced a
mammary-gland specific DNMT1 gene deletion to mice predisposed to breast
cancer, and 85% of the mice were protected. Although the breast development was
suppressed, the DNMT1 gene deleted mice had a significantly higher survival rate
than those who retained the DNMT1 gene in their mammary gland (Pathania et al.
2015). These results indicate that DNMT1 expression in mammary cells could prove
to be an effective target in limiting tumorigenesis in the breast.
Different epigenetic drugs have been created over the years in hopes of
limiting DNMT activity, but no exceptional cancer treatment has been found. The
epigenetic drug 5-azacytidine (AZA) is a known nucleoside DNMT inhibitor that was
approved by the US Food and Drug Administration to treat myelodysplastic
syndrome (Amatori et al. 2010). AZA is one of the few known DNMT inhibiting
drugs and is currently in a number of clinical trials to test its efficacy for the
treatment of haematological cancers. Although AZA was first synthesized over 4
decades ago, the mechanisms behind this epi-drug were not fully understood until
quite recently. AZA’s effectiveness and anti-cancer ability stems from its core
structure, which is notably similar to the structure of the nucleoside base, cytosine.
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Figure 2: The similar structures of Cytosine and 5-Azacytosine. Note the
substitution of a Nitrogen atom at C-5. (Borin et al. 2017)

Once it has been internalized into the cell, AZA is able to incorporate itself
into either DNA or RNA by taking the place of a cytosine base (Amatori et al. 2010).
Specifically in DNA incorporation, after DNA replication takes place, DNMT1
enzymes proceed with their maintenance methylation, but problems arise as they
encounter AZA bases in the DNA. When a DNMT1 binds to an AZA base, the enzyme
is unable to add a methyl group because the C-5 of AZA is replaced with a Nitrogen
atom (Carey, 201). The DNMT1 becomes covalently stuck to the AZA base and is
later degraded, therefore reducing the amount of DNMT1 available (Carey, 201).
This binding and degradation of DNMT1 leads to a passive decrease in methylation
and the re-expression of tumor suppressor genes and apoptotic pathway genes that
had been previously silenced by hypermethylation (Amatori et al. 2010). However,
AZA, like many other potential anti-cancer drugs, has a dangerous toxicity profile
and a high level of instability under physiological conditions (Amatori et al. 2010). It
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must be taken in very low doses to avoid extreme cytotoxicity. If another DNMT
inhibiting compound was found to be similarly effective and have limited adverse
effects, it could prove to be a novel cancer therapeutic.
Natural products are an encouraging area of research because many natural
compounds have exhibited chemopreventive characteristics while maintaining a
low toxicity profile. There are numerous herbal remedies that have shown promise
in the treatment of cancer, and some molecules derived from natural products have
already been reported as having DNMT inhibiting abilities. The marine sponge
Pseudoceratina purpurea contains several derivatives that exhibit DNMT1 inhibitory
abilities, as does a type of red alga by the name of Peyssonnelia caulifera (MedinaFranco et al. 2010). The National Center for Natural Products Research here at the
University of Mississippi has taken a special interest in the roots and rhizomes of the
plant Dioscorea villosa, also known as the wild yam. Found throughout the Eastern
United States, Dioscorea villosa is commonly used as a dietary supplement to treat
menstrual cramps and menopausal symptoms, but has recently shown promise as
an anti-cancer agent (Aumsuwan et al. 2015). The roots and rhizomes of Dioscorea
villosa are rich in steroidal saponins; some of these saponins show promise as anticancer agents (Aumsuwan et al. 2016). Dioscorea villosa root extract was recently
found to decrease the cell viability in several breast cancer cell lines, and was
identified as a possible demethylating agent (Aumsuwan et al. 2015). Further
examination into the components of the root extract revealed that the bioactive
compound dioscin was a major factor responsible for this epigenetic activity.
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Figure 3: The chemical structure of Dioscin. (Aumsuwan et al. 2016)

Dioscin (DS) is a steroidal saponin that has been reported to possess antiinflammatory, hepatoprotective, and antiviral effects (Wu et al. 2015; Zhang et al.
2015; Liu et al. 2012). DS has also been shown to possess anti-proliferative and
apoptotic abilities in a variety of cancer cells (Aumsuwan et al. 2016). In a previous
study (Aumsuwan et al. 2016), DS was found to reduce cell proliferation in two
separate breast cancer cell lines: MCF-7 (estrogen receptor positive; noninvasive)
and MDA-MB-231 (estrogen receptor negative; invasive). A RT-qPCR was also
utilized to determine the effect of DS and AZA (a known DNMT inhibitor) on the
mRNA content of two commonly hypermethylated tumor suppressor genes in
breast cancer: GATA3 and CDH1. DS and AZA were ineffective in altering GATA3 and
CDH1 mRNA expression in the MCF-7 cell line, but both DS and AZA were able to
significantly increase GATA3 and CDH1 mRNA content in the MDA-MB-231 cells.
These results first tell us that the cellular effects of DS and AZA treatments are cell
line specific. In addition, these results indicate that DS may be able to alter the
14

methylation status on the GATA3 and CDH1 gene promoters in invasive breast
cancer cells. An additional RT-qPCR was run to examine the mRNA content of
DNMT1 in MCF-7 and MDA-MB-231 cells treated with DS, and no significant change
was found. From these results, it was hypothesized that DS may have anti-cancer
potential similar to AZA because it is able to affect gene methylation and re-express
tumor suppressor genes that were previously silenced.
The research I conducted is essentially an extension of what was found in the
paragraph above. Because DS and AZA had similar effects in the breast cancer cell
lines, I wanted to determine if DS is able to work through a similar mechanism as
AZA, and if so, if DS could be a novel and safe breast cancer therapeutic. DNMT1 was
the apparent starting point because of its critical role in cell maintenance, and
because it is known to be overexpressed in mammary tumors. Therefore, the goal of
my experiment was to determine if DS is able to inhibit DNMT1 protein expression
in breast cancer cells.

15

Materials and Methods

Plant Material
Dioscin (3β, 25R)-spirost-5-en-3-yl O-α-L-rhamnopyranosyl-(1 → 2)-O-[α-Lrhamnopyranosyl-(1 → 4)]-β-D-glucopyranoside) was isolated at the National
Center for Natural Products Research (NCNPR), University of Mississippi,
Mississippi, USA; the identity and purity (91.2%) were confirmed by
chromatographic and spectral analysis.

Cell Culture
Human breast cancer adenocarcinoma, MCF-7 (ER+) and MDA-MB-231 (ER-) cell
lines were purchased from American Type Culture Collection (ATCC). Both cell lines
were maintained in phenol red free DMEM-F12 (1:1) medium supplemented with
10% dextran charcoal treated fetal bovine serum (Atlanta Biologicals, Atlanta, GA),
50 U/mL penicillin and 50 μg/mL streptomycin as Pen-Strep (Life Technology,
Grand Island, NY), and 2 mM of L-glutamine (Life Technology) at 37°C in a
humidified atmosphere of 95% air and 5% CO2. To maintain both cell lines in
identical culture conditions, human recombinant insulin (0.01 mg/mL) was omitted
for MCF-7 cells. The cells (~400 x 103 cells/mL) were allowed to attach in the
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culture flasks, and after 24 hours were treated with various concentrations of DS (3,
6 μM) or AZA (1μM)(Sigma-Aldrich, St. Louis, MO) as a known inhibitor of DNMT
enzyme activities for three days. The media of the cells treated with AZA were
replaced every 24 hours. After total removal of the media at 72 hours of treatment,
the cells were trypsinized, resuspended in the medium, washed twice with PBS, and
were used for biochemical analysis. (Aumsuwan et al. 2016)

Cell Lysis
Cells were put on ice and kept at a temperature of 4°C. The medium was removed by
aspiration and cells were washed twice with PBS. Cells were treated with 150 μL
lysis buffer (1 mL 10x protease inhibitor, 9 mL lysis buffer) and allowed to incubate
for 1 hour at 4°C. Cells were mechanically removed via scraping and centrifuged at
12,000 rpm for 20 minutes. Supernatant was gathered and protein concentration
was measured via Bradford protocol.

Western Blot
Lysate samples were boiled in sample buffer and loaded onto SDS-PAGE gel
(BioRad) with a concentration of 25 μg of protein in each well. The gel was run at
70 V, 400 mA for 2 hours, and was then transferred onto a blotting membrane and
placed in a blocking solution (Invitrogen; BSA based) overnight at 4°C. The
membrane was rinsed and allowed to incubate with the polyclonal rabbit DNMT1
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IgG antibody (1:100; Santa Cruz Biotechnology; sc-20701) for 24 hours at 4°C.
WesternDot™ 625 Western Blot Kit from Invitrogen was then utilized for
immunodetection of proteins. With washing in between each step, the membrane
was incubated with the goat anti-rabbit IgG secondary antibody (5:12000) for 1
hour at 4°C and the Qdot® 625 streptavidin conjugate (5:12000) for 1 hour at 4°C.
Pictures were taken of the membrane and analyzed. Anti-beta Actin antibody (Cell
Signaling) was utilized as a loading control.
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Results and Observations

Two separate Western blots were run to give an accurate representation of
dioscin’s effects on the DNMT1 protein. For each Western blot, both cell lines
received the following treatments: Dimethyl sulfoxide (DMSO) only, 1μM AZA, 3μM
DS, and 6μM DS. Both DS and AZA had been resuspended in DMSO in their stock
solutions, so the DMSO only treatment served as our control. This made sure that
the observed results were due to DS and AZA, and not due to the DMSO.
The image of Western blot 1 (Figure 4) was taken September 28, 2016. The
MDA-MB-231 cells proved to be much more fragile in culture than the MCF-7 cells.
The treatment of 6μM DS was found to be toxic to the MDA-MB-231 cells, and we
were not able to collect enough lysate for western blot analysis. Therefore, the
treatment of 6μM DS was omitted for the MDA-MB-231 cells in Western blot 1
(Figure 4). Two separate isoforms of DNMT1 protein were detected on the
membrane, which is consistent with the background information given by Santa
Cruz Biotechnology and expected because of the polyclonal nature of the antibody.
The first isoform (A) was detected at roughly 145 kDa, while the second isoform (B)
was detected at 120 kDA. The loading control was confirmed to be accurate, as the
beta Actin bands (C) were located at the expected weight of 45 kDa.
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Lane:

1

2

3

4

5

6

7

8

9

10

A
B
75 kDa

C

25 kDa

Figure 4: Western blot 1 analysis of the cell lines MCF-7 (lanes 2-6) and MDA-MB231 (lanes 7-10) with selected treatments. Lane 1: molecular weight markers; Lane
2: MCF-7, DMSO; Lane 3: MCF-7, 1μM AZA; Lane 4: MCF-7, 6μM DS; Lane 5: MCF-7,
3μM DS; Lane 6: MCF-7, untreated; Lane 7: MDA-MB-231, DMSO; Lane 8: MDA-MB231, 1μM AZA; Lane 9: MDA-MB-231, 3μM DS; Lane 10: MDA-MB-231, untreated.

The image of Western blot 2 (Figure 5) was taken November 11, 2016. The
MDA-MB-231 cells responded more favorably to the 6μM DS treatment, and we
were able to collect enough lysate for western blot analysis. The 6μM DS lane was
therefore added for the MDA-MB-231 cell line in Western blot 2 (Figure 5, lane 8).
The two DNMT1 isoforms (A,B) were detected at 145 kDa and 120 kDa, and the beta
Actin bands were again located at 45 kDa. While there is a significant amount of
non-specific binding and background noise in between the beta Actin bands and the
20

DNMT1 bands, this can be chiefly attributed to the polyclonal nature of the DNMT1
antibody. If a monoclonal antibody were used, the binding would be much more
specific.

Lane: 1

2

3

4

5

6

7

8

9

A
B
75 kDa

C

25 kDa

Figure 5: Western blot 2 analysis of cell lines MCF-7 (lanes 2-5) and MDA-MB-231
(Lanes 6-9) with selected treatments. Lane 1: molecular weight markers; Lane 2:
MCF-7, DMSO; Lane 3: MCF-7, 1μM AZA; Lane 4: MCF-7, 6μM DS; Lane 5: MCF-7,
3μM DS; Lane 6: MDA-MB-231, DMSO; Lane 7: MDA-MB-231, 1μM AZA; Lane 8:
MDA-MB-231, 6μM DS; Lane 9: MDA-MB-231 3μM DS.

The intensities of the DNMT1 protein bands were quantified using the BioRad ChemiDoc MP Imaging System. The intensities for each of the treatments were
normalized in terms of the control (DMSO only), and relative intensity ratios were
developed to analyze the DNMT1 protein concentrations.
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Table 1: Relative intensity ratios of DNMT1 protein bands for Western blot 1.
Treatment

Antibody

Cell line

First Isoform

Second Isoform

DMSO

DNMT1

MCF7

1.00

1.00

1uM AZA

DNMT1

MCF7

0.39

0.64

6uM DS

DNMT1

MCF7

0.78

0.72

3uM DS

DNMT1

MCF7

1.04

1.00

DMSO

DNMT1

MDAMB231

1.00

1.00

1uM AZA

DNMT1

MDAMB231

0.68

1.07

3uM DS

DNMT1

MDAMB231

0.47

1.41

Table 2: Relative intensity ratios of DNMT1 protein bands for Western blot 2.
Treatment

Antibody

Cell line

First Isoform

Second Isoform

DMSO

DNMT1

MCF7

1.00

1.00

1uM AZA

DNMT1

MCF7

0.21

0.76

6uM DS

DNMT1

MCF7

0.51

0.90

3uM DS

DNMT1

MCF7

0.54

1.00

DMSO

DNMT1

MDAMB231

1.00

1.00

1uM AZA

DNMT1

MDAMB231

0.63

1.13

6uM DS

DNMT1

MDAMB231

0.70

1.21

3uM DS

DNMT1

MDAMB231

0.68

1.11

The results in Table 1 and Table 2 indicate that DS and AZA were able to decrease
the protein concentration of the first isoform of DNMT1 in both the MCF-7 cells and
the MDA-MB-231 cells. However, only the 1μM AZA and the 6μM DS treatments
were able to inhibit the protein expression of the second DNMT1 isoform. These
relationships are more clearly depicted by Figure 6.

22

Figure 6: Mean expression of DNMT1 protein (± average deviation) for Western
blots 1 and 2.

Figure 6 demonstrates that DS and AZA were much more effective in decreasing
the protein expression of the first DNMT1 isoform in both the MCF-7 and MDA-MB231 cell lines. Protein expression for both DNMT1 isoforms exhibited a dose dependent
response to DS in the MCF-7 cells. AZA was also able to decrease the protein expression
of the first isoform of DNMT1 by 70% and the second isoform of DNMT1 by 30%.
Protein expression in the MDA-MB-231 cells did not exhibit a dose dependent response
to DS. DS and AZA were able to decrease protein expression of the first isoform of
DNMT1 in the MDA-MB-231 cells, but they actually increased protein expression of the
second isoform of DNMT1.
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Table 3: The percent increase/decrease of DNMT1 protein concentration in breast
cancer cells.
MCF7

Treatment DNMT1
isoform 1
AZA 1uM 70% decrease
DS 3uM
21% decrease
DS 6uM
36% decrease

MDAMB231

DNMT1
isoform 2
30% decrease
no decrease
19% decrease
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DNMT1
isoform 1
34% decrease
30% decrease
42% decrease

DNMT1
isoform 2
10% increase
26% increase
21% increase

Discussion

The present study was focused on the steroidal saponin, dioscin, and its
efficacy as a DNMT1 inhibitor. The results obtained from the two Western blot
experiments are not perfect, but they are promising. DS was able to inhibit the
protein expression of both isoforms of DNMT1 in MCF-7 cells and the protein
expression of the first isoform (145 kDa) of DNMT1 in MDA-MB-231 cells. DS and
AZA exhibited similar effects on the DNMT1 protein concentration, as we hoped
they would. These complementary results reinforce our hypothesis that DS is a
potential DNMT1 inhibitor. It can also be concluded that DS is acting posttranscriptionally to inhibit DNMT1 protein expression. We know this because the
mRNA content of DNMT1 in MCF-7 and MDA-MB-231 cells remained unaltered
when treated with DS (Aumsuwan et al. 2016). Therefore, DS may be acting on the
DNMT1 mRNA and inhibiting some step of translation, or DS may be directly
degrading the DNMT1 protein with a mechanism similar to AZA’s.
While these results support our hypothesis that DS is a DNMT1 inhibitor,
there are still some questions that remain. DS was able to inhibit DNMT1 protein
expression in the MCF-7 cells; this was not expected considering that in a previously
conducted experiment, DS increased GATA3 and CDH1 mRNA expression in the
MDA-MB-231 cells but not in the MCF-7 cells (Aumsuwan et al. 2016). For this
reason, DS’s inhibition of DNMT1 may not be the only contributing factor in the re25

expression of GATA3 and CDH1. Analysis of DS’s effect on other epigenetic proteins
may be needed in order to explain the exact mechanism by which DS is able to reexpress these tumor suppressor genes.
DS is a proven anti-breast cancer agent in vitro. It is able to reduce cell
proliferation and increase expression of crucial tumor suppressor genes. Whether
or not DS’s anti-breast cancer potential stems solely from its DNMT1 inhibiting
activity remains to be seen, but there is a clear path to follow in order to determine
this. The effect of DS on other epigenetic proteins involved in methylation and
demethylation must be determined. DS’s impact on DNMT3A and DNMT3B protein
expression should be examined, as well as its impact on other DNMT binding
proteins and the recently discovered TET enzymes. As our knowledge in the field of
epigenetics increases, so will our knowledge on epigenetic mechanisms and drug
treatments. DS may one day be used as an anti-invasive therapeutic in the treatment
of breast cancer, but we have yet to elucidate the exact mechanism of action or how
it will perform in an animal model. For now, DS is a promising and natural anticancer agent with the potential to limit DNMT1 protein expression, and therefore
methylation, in breast cancer cells in vitro.
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